Estrogen receptor (ER)

Similar documents
Estrogen receptor (ER)

Estrogen receptor (ER)

Thyroid transcription factor-1 (TTF1) Assessment run

Assessment Run GATA3

Carcinoembryonic antigen (CEA)

SMH (Myosin, smooth muscle heavy chain)

Cytokeratin 19 (CK19)

Assessment Run B HER-2 IHC. HER-2/chr17 ratio**

Sal-like protein 4 (SALL4)

Assessment Run

Epithelial cell-cell adhesion molecule (Ep-CAM)

Assessment Run B HER2 IHC

Lung Anaplastic Lymphoma Kinase (lu-alk)

Assessment Run CK19

Assessment Run B HER2 IHC

Assessment Run NKX3.1 (NKX3.1)

Assessment Run C1 2017

Assessment Run C3 2018

HER2 ISH (BRISH or FISH)

Optimization of antibodies, selection, protocols and controls Breast tumours

Breast cancer: Antibody selection, protocol optimzation controls and EQA

Assessment Run B HER-2

Quality Assurance in Immunohistochemistry: Experiences from NordiQC

10 years of NordiQC Why are 30% of labs still getting it wrong?

External Quality Assessment of Breast Marker Analysis. NordiQC data

External Quality Assessment of melanocytic marker analyses NordiQC experience

IHC Stainer platforms. Overview, pros and cons

NordiQC - update

Product Introduction. Product Codes: HCL029, HCL030 and HCL031. Issue

Assessment performed on Tuesday, July 29, 2014, at Lions Gate Hospital, North Vancouver

Assessment performed on Friday, September 18, 2015, at Vancouver General Hospital

Nordic Immunohistochemical Quality Control

NordiQC External Quality Assurance in Immunohistochemistry

Image analysis in IHC overview, considerations and applications

Immunohistochemical principles The technical test approach. Pre-analytical parametres

Supplementary Online Content

The unknown primary tumour: IHC classification part I, the primary panel - Antibody selection, protocol optimization, controls and EQA

HPV/p16 Analyte Control

The impact of proficiency testing on lab immunoassays

IDH1 R132H/ATRX Immunohistochemical validation

The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part I)

Single and Multiplex Immunohistochemistry

Breast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark

Diagnostic IHC in lung and pleura pathology

A National Quality Assurance program for breast immunohistochemistry: an Italian perspective

HistoCyte Laboratories Ltd

Protocols for Zytomed Systems antibodies on fully automated IHC staining systems date of issue: September 20, 2012

Immunocytochemistry. Run 119/48. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images

Supplemental Data Table 1 Characteristics of the MHH BC cohort number percent cases histology IDBC ILBC others 6 3 pt status pt1

Immunotherapy in NSCLC Pathologist role

Milestones in Her 2 Testing

# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer

Results you can trust

PD-L1 Analyte Control DR

VENTANA MMR IHC Panel Interpretation Guide for Staining of Colorectal Tissue

Supplemental figure 1. PDGFRα is expressed dominantly by stromal cells surrounding mammary ducts and alveoli. A) IHC staining of PDGFRα in

Histopathology: Cervical HPV and neoplasia

Immunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers

Immunocytochemistry. Run 113/42. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images

Immunohistochemical classification of the unknown primary tumour (UPT) Part I. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark

Product Introduction

Vernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we

HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer

Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods

VENTANA PD-L1 (SP142) Assay Guiding immunotherapy

Brief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies

VENTANA PD-L1 (SP142) Assay

Molecular Probes Introducing 14 new probes

Predictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al -

Immunohistochemical classification of lung carcinomas and mesotheliomas. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark

Objectives. Atypical Glandular Cells. Atypical Endocervical Cells. Reactive Endocervical Cells

Immune Cell Phenotyping in Solid Tumors using Quantitative Pathology

NSCLC. Harmonization study 1. Lung cancer and other malignancies -PD-L1 assay, QuIP EQA

Immunocytochemistry. Results - Summary Graphs - Pass Rates Best Methods - Selected Images. Run 100. Assessment Dates: 3 rd - 22 nd January 2013

Lower 1D5 Sensitivity but Questionable Clinical Implications

VENTANA PD-L1 (SP142) Assay Guiding immunotherapy in NSCLC

Simultaneous de-waxing and standardisation of antigen retrieval in immunohistochemistry using commercially available equipment

Classification of the unknown primary tumour: the primary IHC panel

ONCO TEAM DIAGNOSTIC

Immunocytochemistry. Run 120/49. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images

Immunohistochemistry on Fluid Specimens: Technical Considerations

Predictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.

Supplementary Appendix

What kind of material should we use for ICC in our daily routine. Torill Sauer Department of Pathology, Akershus University Hospital

COMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME

Bond Ready-to-Use Primary Antibody Progesterone Receptor (16)

PD-L1 IHC 22C3 pharmdx. SK tests for use with Autostainer Link 48 Table of Contents

Speaking to you. This statement by Dr. Rodney T. Miller, Director of

Diagnostically Challenging Cases in Gynecologic Pathology

Interpretation guide. Abnormal cytology can t hide anymore

Cell Culture. The human thyroid follicular carcinoma cell lines FTC-238, FTC-236 and FTC-

Anti-PD-L1 antibody [28-8] ab205921

Quality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024

Thermo Scientific UltraVision Quanto for Immunohistochemistry The New Generation Micro-Polymer Detection System

HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer

Breast cancer diagnostic solutions Deliver diagnostic confidence

Immunohistochemistry. Potential and challenges To be or not to be

Cluster designation 5 staining of normal and non-lymphoid neoplastic skin*

Patterns of E.cadherin and Estrogen receptor Expression in Histological Sections of Sudanese Patients with Breast Carcinoma

Transcription:

Assessment Run B7 204 Estrogen receptor (ER) Material The slide to be stained for ER comprised: No. Tissue ER-positivity* ER-intensity*. Uterine cervix 80-90% Moderate to strong 2. Breast carcinoma 0% Negative 3. Breast carcinoma** 40-60% Weak to moderate 4. Breast carcinoma 60-90% Weak to moderate 5. Breast carcinoma 90-00% Moderate to strong *ER-status and staining pattern as characterized by NordiQC reference laboratories using the mab clone SP. ** In some slides the tissue was partially detached and the evaluation was performed on the remaining 4 tissues. All tissues were fixed in 0% neutral buffered formalin for 24-48 hours and processed according to Yaziji et al. (). Criteria for assessing ER staining result as optimal were: Moderate to strong, distinct nuclear staining reaction of virtually all columnar epithelial cells, basal squamous epithelial cells and most stromal cells (except endothelial and lymphoid cells) in the uterine cervix. At least weak to moderate distinct nuclear staining reaction in the appropriate proportion of the neoplastic cells in the breast carcinomas no. 3, 4 and 5. No nuclear staining reaction of neoplastic cells in the breast carcinoma no. 2. No more than a weak cytoplasmic staining reaction in cells with strong nuclear staining reaction. The staining reactions were classified as good if 0 % of the neoplastic cells in the breast carcinomas no. 3, 4 and 5 showed an at least weak nuclear staining reaction (but less than the range of the reference laboratories). The staining reactions were classified as borderline if % and < 0 % of the neoplastic cells showed a nuclear staining reaction in one or more of the breast carcinomas no. 3, 4 & 5. The staining reactions were classified as poor if a false negative or false positive staining reaction was seen in one of the breast carcinomas. Results 28 laboratories participated in this assessment. 248 (88%) achieved a sufficient mark (optimal or good). Antibodies (Abs) used and assessment marks are summarized in table (see page 2). Conclusion The rmab clones EP and SP were in this assessment the most robust Abs for demonstration of ER. The Ready-To-Use (RTU) format of the (Ventana) provided the highest proportion of sufficient and optimal results. In this assessment, false negative staining reactions were prominent features of insufficient staining results. Uterine cervix is an appropriate positive tissue control for ER. Virtually all stromal, columnar epithelial and squamous epithelial cells must show a moderate to strong and distinct nuclear staining reaction. Lymphocytes and endothelial cells must be negative. Nordic Immunohistochemical Quality Control, ER run B7 204 Page of 7

Table. Antibodies and assessment marks for ER, run B7 Concentrated antibodies mab clone D5 mab clone 6F rmab clone EP Ready-To-Use antibodies mab clone D5 IS/IR657 mab clone 6F PA05 mab clones D5+ER-2-23 K407 rmab clone EP IS/IR084 790-4324/25 n Vendor Optimal Good Borderline Poor 6 3 28 2 7 25 3 2 Dako Immunologic Zytomed Leica/Novocastra Monosan Vector Dako Epitomics Thermo/NeoMarkers Immunologic Spring Bioscience Cell Marque Suff. Suff. OPS 2 0 6 2 2 60% - 9 0 65% 68% 3 0 3 2 72% 00% 2 9 0 97% 96% 2 Dako 2 6 3 67% 75% 5 Leica/Novocastra 0 2 3 0 40% - Dako 0 0 0 - - 42 Dako 2 25 5 0 88% 92% 28 Ventana 8 0 0 0 00% 00% IR5* RM-90-R7 MAD-000306QD Dako 0 0 0 - - Thermo/NeoMarkers 0 0 0 - - Master Diagnostica 0 0 0 - - Total 28 69 79 27 6 - Proportion 60% 28% 0% 2% 88% ) Proportion of sufficient stains (optimal or good) 2) Proportion of sufficient stains with optimal protocol settings only, see below *product discontinued Detailed analysis of ER, Run B7 The following protocol parameters were central to obtain an optimal staining reaction Concentrated antibodies mab clone 6F: Protocols with optimal results were all based on HIER using TRS ph 9 (Dako) (/3), Cell Conditioning (CC; Ventana) (/6), Bond Epitope Retrieval Solution 2 (BERS2; Leica) (5/3), BERS (Leica) (2/3), PT module buffer ph 6 (Thermo) (/) or Tris-EDTA/EGTA ph 9 (/3) as retrieval buffer. The mab was typically diluted in the range of :50-:200 depending on the total sensitivity of the protocol employed. Using these protocol settings 5 of 22 (68%) laboratories produced a sufficient staining result (optimal or good). rmab clone EP: Protocols with optimal results were all based on HIER using TRS ph 9, 3-in- (Dako) (/0), TRS ph 9 (Dako) (/5) or BERS 2 (Leica) (/) as retrieval buffer. The rmab was diluted in the range of :25-:30 depending on the total sensitivity of the protocol employed. Using these protocol settings 3 of 3 (00%) laboratories produced an optimal staining result. : Protocols with optimal results were all based on HIER using TRS ph 9, 3-in- (Dako) (2/3), CC (BenchMark, Ventana) (6/), BERS 2 (Leica) (6/6), Tris-EDTA/EGTA ph 9 (5/6) or Citrate ph 6 (2/3) as retrieval buffer. The rmab was diluted in the range of :30-:00 depending on the total sensitivity of the protocol employed. Using these protocol settings 27 of 28 (96%) laboratories produced a sufficient staining result. Nordic Immunohistochemical Quality Control, ER run B7 204 Page 2 of 7

Table 2. Optimal results for ER using concentrated antibodies on the 3 main IHC systems* Concentrated antibodies Dako Autostainer Link / Classic Ventana BenchMark XT / Ultra Leica Bond III / Max TRS ph 9.0 TRS ph 6. CC ph 8.5 CC2 ph 6.0 ER2 ph 9.0 ER ph 6.0 mab clone 6F 0/2** - /5 (20%) - 5/8 (63%) /2 rmab clone EP 2/2 - - - / - rmab clone SP 2/4-6/0 (60%) - 6/6 (00%) - * Antibody concentration applied as listed above, HIER buffers and detection kits used as provided by the vendors of the respective platforms. ** (number of optimal results/number of laboratories using this buffer) Ready-To-Use antibodies and corresponding systems mab clone D5, product no. IS/IR657, Dako, Autostainer+/Autostainer Link: Protocols with optimal results were based on HIER in PT-Link using TRS ph 9 (3-in-) or TRS ph 9 (efficient heating time 5-20 min. at 97 C), 20 min incubation of the primary Ab and EnVision FLEX/FLEX+ (K8000/K8002) as detection system. Using these protocol settings 3 of 4 laboratories produced a sufficient staining result (optimal or good). rmab clone EP, product no. IS/IR084, Dako, Autostainer+/Autostainer Link: Protocols with optimal results were typically based on HIER in PT-Link using TRS ph 9 (3-in-) or TRS ph 9 (efficient heating time 0-20 min. at 95-98 C), 20-30 min incubation of the primary Ab and EnVision FLEX/FLEX+ (K8000/K8002) as detection system. Using these protocol settings 34 of 37 (92%) laboratories produced a sufficient staining result., product no. 790-4324/25, Ventana, BenchMark GX/XT/Ultra: Protocols with optimal results were all based on HIER using short, mild or standard Cell Conditioning, 8-64 min incubation of the primary Ab and Iview (760-09), UltraView (760-500, +/- amplification kit) or OptiView (760-700) as detection system. Using these protocol settings 28 of 28 (00%) laboratories produced a sufficient staining result. The most frequent causes of insufficient stainings were: - Insufficient HIER (too short efficient HIER time) - Too low concentration of the primary Ab. In this assessment, the prominent feature of an insufficient staining result was a too weak or false negative staining reaction. This pattern was seen in 94% of the insufficient results (3 of 33) and was typically caused by insufficient HIER and/or too low titre of the primary Ab irrespectively of clone applied. Virtually all laboratories were able to demonstrate ER in the high level ER expressing breast carcinoma no. 5 in which 90-00% of the neoplastic cells were expected to show a moderate to strong nuclear staining reaction. Demonstration of ER in the breast carcinomas no. 4 and especially no. 3 in which at least a weak nuclear staining of 40-90 % of the neoplastic cells was expected, were much more challenging and required an optimally calibrated protocol. The rmab clones EP and SP were the most successful Abs, and in particular the Ventana RTU format of the provided a high proportion of sufficient and optimal results. Optimal result could be obtained both by the official recommended protocol (6 min incubation of the primary Ab, HIER in CC for 64 min and UltraView as detection kit) and by laboratory defined modifications of the protocol e.g. prolonged of incubation time of the primary Ab and/or reduced HIER time. The concentrated format of the could be used to obtain optimal staining result on the IHC systems from Dako, Leica and Ventana, see table 2. Performance history This was the 3 th NordiQC assessment of ER. A slight increase in the proportion of sufficient results was seen compared to the latest runs (Figure ). Nordic Immunohistochemical Quality Control, ER run B7 204 Page 3 of 7

Fig.. Participant numbers and Pass rates for ER during 3 runs As seen in previous runs for ER, an important factor to obtain and maintain the high pass rates was the impact from the extended use of properly calibrated RTU systems for ER instead of laboratory developed assays. For example, the RTU systems in the current run grouped together provided a pass rate of 94% (79 of 9 laboratories) compared to 77% (69 of 90 laboratories) for laboratory developed assays for ER. In this context it has to be mentioned, that the Ventana RTU system based on the provided a pass rate of 00% and was used by 28 of the 9 laboratories using RTU systems for ER. Controls In concordance with previous NordiQC runs, uterine cervix was found to be an appropriate and recommendable positive tissue control for ER staining: In optimal protocols, virtually all epithelial cells throughout the layers of the squamous epithelium and in the glands showed a moderate to strong and distinct nuclear staining reaction. In the stromal compartment, moderate to strong nuclear staining reaction was seen in most cells except endothelial and lymphatic cells. If the staining intensity in the epithelial cells of the uterine cervix was significantly reduced, a too weak or even false negative staining was seen in the breast carcinomas no. 3 and 4. In order to validate the specificity of the IHC protocol, ER negative breast carcinoma must be included in which only remnants of normal epithelial and stromal cells must be ER positive serving as internal positive tissue control. Positive staining reaction of the stromal cells breast tissue indicates that a high sensitive protocol is being applied, whereas the sensitivity cannot be evaluated in the normal epithelial cells as they express high levels of ER. Nordic Immunohistochemical Quality Control, ER run B7 204 Page 4 of 7

Fig. a Optimal ER staining of the uterine cervix using the rmab clone SP optimally calibrated and with HIER in an alkaline buffer. Virtually all the squamous and columnar epithelial cells show a moderate to strong, distinct nuclear staining reaction. The majority of the stromal cells are demonstrated and only endothelial and lymphoid cells are negative. Fig. b Insufficient ER staining of the uterine cervix, same field as in Fig. a. The proportion and intensity of the staining reaction in the squamous and especially in columnar epithelial cells are reduced. Also compare with Figs. 2b - 4b same protocol. The protocol was based on the mab clone 6F applied with protocol settings giving a too low sensitivity most likely a too dilute titre of the primary Ab. Fig. 2a Left: Optimal ER staining of the breast ductal carcinoma no. 5 with 80 00% cells strongly positive using same protocol as in Fig. a. Virtually all the nuclei of the neoplastic cells show a strong, distinct nuclear staining reaction with only a weak cytoplasmic staining reaction. No background staining is seen. Right: No staining reaction in the ER negative breast carcinoma no. 2 is seen. Fig. 2b ER staining of the breast ductal carcinoma no. 5 with 80 00% cells positive using the same protocol as in Fig. b same field as in Fig. 2a. Virtually all the neoplastic cells are demonstrated, but also compare with Figs. 2b - 4b same protocol. Nordic Immunohistochemical Quality Control, ER run B7 204 Page 5 of 7

Fig. 3a Optimal ER staining of the breast ductal carcinoma no. 4 with 60 90% cells positive. A weak to moderate, distinct nuclear staining in the appropriate proportion of the neoplastic cells is seen. Same protocol as in Figs. a and 2a. Fig. 3b Insufficient ER staining of the breast ductal carcinoma no. 4 with 60 90% cells positive using same protocol as in Figs. b and 2b same field as in Fig. 3a. More than 0% of the neoplastic cells are demonstrated, but the proportion and intensity is significantly reduced compared to level expected and obtained in Fig. 3a. Also compare with Fig. 4b - same protocol. Fig 4a Optimal ER staining of the breast ductal carcinoma no. 3 with 50 80% cells positive. A weak but distinct nuclear staining reaction is seen in the appropriate proportion of the neoplastic cells and no background staining is seen. Same protocol as in Figs. a 3a Fig 4b Insufficient ER staining of the breast ductal carcinoma no. 3 with 50 80% cells positive using same protocol as in Figs. b - 3b same field as in Fig. 4a. A false negative staining reaction is seen. Nordic Immunohistochemical Quality Control, ER run B7 204 Page 6 of 7

Fig. 5a Insufficient ER staining of the uterine cervix, same field as in Fig. a. Virtually no nuclear staining reaction in the squamous epithelial cells, columnar epithelial cells and stromal cells is seen. Also compare with Figs. 5b left and right, same protocol. A combination of a too low titre of the primary Ab, insufficient HIER and excessive counterstaining provided a too low sensitivity of the protocol. Fig. 5b Left: ER staining of the breast ductal carcinoma no. 5 with a high level of ER expression. The vast majority of the neoplastic cells are demonstrated as expected. Right: Insufficient and false negative staining result of the breast ductal carcinoma no. 4 with a moderate level of ER expression (60 90% cells positive, weak to moderate intensity). Using the protocol as shown in Figs. 5a and 5b both the breast ductal carcinomas no. 3 and 4 were false negative. SN/RR/MV/LE 08-04-204 Nordic Immunohistochemical Quality Control, ER run B7 204 Page 7 of 7